


=> d l1
 L1 HAS NO ANSWERS
 L1 STR



G1 H, X, Ak, NO2

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 06:51:32 ON 25 JUN 2003)

FILE 'REGISTRY' ENTERED AT 06:51:40 ON 25 JUN 2003

L1 STRUCTURE UPLOADED
 L2 7 S L1
 L3 84 S L1 FULL
 L4 84 S L3 AND CAPLUS/LC
 L5 0 S L3 AND CAOLD/LC

FILE 'CAPLUS' ENTERED AT 06:52:56 ON 25 JUN 2003

L6 3 S L3

aryl, heterocyclyl, lower alkyl-lower cycloalkyl, aryl-lower alkyl, or heterocyclyl-lower alkyl; Nu = 5- or 6-membered ring; X and Nu may be directly linked to each other; R1 = H, halo, lower alkyl, NH2, acylamino, lower alkyl alkenyl, alkynyl, halo-lower alkyl, lower cycloalkyl, NO2, lower alkyl-amino, CO2H or its ester, amidated CO2H, lower alkanesulfonyl, arylsulfonyl, OH, lower alkoxy; n = integer of .ltoreq.2; A = (un)substituted aryl or pharmaceutically acceptable salts thereof are prepd. Because of having hypoglycemic and PDE 5 inhibitory activities, these compds. and salts thereof are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin-resistant syndrome, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension, angina pectoris, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by disordered intestinal motion, sexual impotence, nephritis, cachexia, pancreatitis, post-(percutaneous transluminal coronary angioplasty) PTCA reconstruction, etc. Thus, (E)-3-(4-bromo-1-(2,4-dichlorobenzyl)-2-methylimidazol-5-yl)-2-propenoic acid was stirred with N,N'-carbonyl diimidazole in DMF at room temp. for 1 h and then condensed with pentanesulfonamide in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene at 100.degree. for 3 h to give the title compd. (II). Another compd., 4-(acetamido)-3-(N-methyl-2,4-dichlorobenzylamino)-[N-(n-pentanesulfonyl)]benzamide (III) (prepn. given), lowered glucose and triglyceride level by 60 and 104%, resp., when a feed contg. 0.01% III was fed to mice twice per wk for 14 days.


IT 219503-80-7P 219503-84-1P 219503-86-3P
219503-88-5P 219503-90-9P 219504-01-5P
219504-02-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-sulfonyl(benzylamino)benzamide, N-sulfonylbenzylimidazolepropanamide, and N-sulfonylpyridinecarboxamide having hypoglycemic and phosphodiesterase 5 inhibitory activities as drugs)

RN 219503-80-7 CAPLUS


CN 2-Propenamide, 3-[4-bromo-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219503-84-1 CAPLUS


CN 1H-Imidazole-5-propanamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)



RN 219503-86-3 CAPLUS

CN 2-Propenamide, 3-[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219503-88-5 CAPLUS

CN 2-Propenamide, 3-[4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219503-90-9 CAPLUS

CN 2-Propenamide, 3-[4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(phenylsulfonyl)-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219504-01-5 CAPLUS

CN 2-Thiophenepropanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219504-02-6 CAPLUS

CN Benzenepropanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT